Tags

Type your tag names separated by a space and hit enter

Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure.
Cardiol Rev. 2006 May-Jun; 14(3):108-24.CR

Abstract

Underlying causes, risk factors, and precipitating causes of heart failure (HF) should be treated. Drugs known to precipitate or aggravate HF such as nonsteroidal antiinflammatory drugs should be stopped. Patients with HF and a low left ventricular ejection fraction (systolic heart failure) or normal ejection fraction (diastolic HF) should be treated with diuretics if fluid retention is present, with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker if the patient cannot tolerate an ACE inhibitor because of cough, angioneurotic edema, rash, or altered taste sensation, and with a beta blocker unless contraindicated. If severe systolic HF persists, an aldosterone antagonist should be added. If HF persists, isosorbide dinitrate plus hydralazine should be added. Calcium channel blockers should be avoided if systolic HF is present. Digoxin should be avoided in men and women with diastolic HF if sinus rhythm is present and in women with systolic HF. Digoxin should be given to men with systolic HF if symptoms persist, but the serum digoxin level should be maintained between 0.5 and 0.8 ng/mL.

Authors+Show Affiliations

Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, New York 10595, USA. WSAronow@aol.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16628020

Citation

Aronow, Wilbert S.. "Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure." Cardiology in Review, vol. 14, no. 3, 2006, pp. 108-24.
Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev. 2006;14(3):108-24.
Aronow, W. S. (2006). Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiology in Review, 14(3), 108-24.
Aronow WS. Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiol Rev. 2006;14(3):108-24. PubMed PMID: 16628020.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. A1 - Aronow,Wilbert S, PY - 2006/4/22/pubmed PY - 2006/9/29/medline PY - 2006/4/22/entrez SP - 108 EP - 24 JF - Cardiology in review JO - Cardiol Rev VL - 14 IS - 3 N2 - Underlying causes, risk factors, and precipitating causes of heart failure (HF) should be treated. Drugs known to precipitate or aggravate HF such as nonsteroidal antiinflammatory drugs should be stopped. Patients with HF and a low left ventricular ejection fraction (systolic heart failure) or normal ejection fraction (diastolic HF) should be treated with diuretics if fluid retention is present, with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker if the patient cannot tolerate an ACE inhibitor because of cough, angioneurotic edema, rash, or altered taste sensation, and with a beta blocker unless contraindicated. If severe systolic HF persists, an aldosterone antagonist should be added. If HF persists, isosorbide dinitrate plus hydralazine should be added. Calcium channel blockers should be avoided if systolic HF is present. Digoxin should be avoided in men and women with diastolic HF if sinus rhythm is present and in women with systolic HF. Digoxin should be given to men with systolic HF if symptoms persist, but the serum digoxin level should be maintained between 0.5 and 0.8 ng/mL. SN - 1061-5377 UR - https://www.unboundmedicine.com/medline/citation/16628020/Epidemiology_pathophysiology_prognosis_and_treatment_of_systolic_and_diastolic_heart_failure_ L2 - http://dx.doi.org/10.1097/01.crd.0000175289.87583.e5 DB - PRIME DP - Unbound Medicine ER -